Premedication for endotracheal intubation in the newborn infant

KJ Barrington; Canadian Paediatric Society
Fetus and Newborn Committee
Paediatr Child Health 2011;16(3):159-64

Abstract
Endotracheal intubation, a common procedure in newborn care, is associated with pain and cardiorespiratory instability. The use of premedication reduces the adverse physiological responses of bradycardia, systemic hypertension, intracranial hypertension and hypoxia. Perhaps more importantly, premedication decreases the pain and discomfort associated with the procedure. All newborn infants, therefore, should receive analgesic premedication for endotracheal intubation except in emergency situations. Based on current evidence, an optimal protocol for premedication is to administer a vagolytic (intravenous [IV] atropine 20 µg/kg), a rapid-acting analgesic (IV fentanyl 3 µg/kg to 5 µg/kg; slow infusion) and a short-duration muscle relaxant (IV succinylcholine 2 mg/kg). Intubations should be performed or supervised by trained staff, with close monitoring of the infant throughout.

Key Words: Bradycardia; Endotracheal intubation; Hypertension; Hypoxia; Newborn; Pain; Premedication

Endotracheal intubation is a common procedure in newborn care. There is great variation in the frequency of premedication use for intubation, and in the medications used \[1,2\]. The experience of being intubated is unpleasant \[3\] and painful \[3,4\], and seriously disturbs the cardiovascular and respiratory status of the newborn. Reducing pain is an ethical obligation for those providing care for newborn infants \[5\]; although nurses and physicians recognize that tracheal intubation of the newborn is a very painful procedure \[4\], they still frequently fail to provide any pain relief \[4\].

The use of such agents does not require indisputable proof that they improve the long-term outcomes of the infants; it is possible that they do not do so. There is no absolute proof that awake intubation adversely affects long-term outcomes in adults undergoing endotracheal intubation, but that is not used as an excuse for performing this painful and unpleasant act without premedication. The infants under our care are more likely to feel pain \[6\] and more likely to have adverse long-term outcomes as a result of the serious pain that they experience during intensive care \[6\], than an adult in similar circumstances. A humane and ethical approach to neonatal intensive care procedures demands the use of preemptive analgesia before planned painful procedures \[7\].

The purpose of the present statement is to review the literature regarding appropriate premedications for intubation and produce evidence-based recommendations for their use.

Methods of statement development

The literature review included a Medline search last updated in June 2010 using PubMed. The following search terms were used: intubation, endotracheal and newborn. The search was limited to human studies in English, French, German or Spanish. The abstracts of the Pediatric Academic Societies were searched for the years 1995 through 2007. A search of Embase was performed for the years 1966 through 2007. The hierarchy of evidence from the Centre for Evidence-Based Medicine was applied using levels of evidence for treatment and prognosis (go to http://www.cebm.net and click on the EBM Tools tab, or go directly to www.cebm.net/index.aspx?o=1025).
Pulmonary hypertension leading to right ventricular failure during intubation has been well described in adults [15], but pulmonary artery pressures have not been measured in newborn infants during intubation.

**What are the effects of premedication on the physiological responses?**

The physiological responses to intubation can be reduced or eliminated by the administration of vagolytics, muscle relaxants, analgesics, preoxygenation and gentle technique. Specifically, bradycardia can be largely prevented by the use of atropine [12]; systemic hypertension can be reduced by adequate analgesia, which also reduces endocrine and endorphin responses [16]; and intracranial hypertension can be avoided by the use of muscle relaxants [13] (all evidence level 1b). Intubation is much faster when the infant is paralyzed [13][17][18], whether performed by experienced neonatologists [13], anaesthetists [18] or paediatric residents [17] (evidence level 1b), which leads to reduced hypoxia. Fewer attempts are also required [19][20].

Two recent studies [19][20] that gave potent analgesics to all infants, randomly assigned the infants to receive muscle relaxants or no relaxants. Both studies demonstrated additional benefits of giving a muscle relaxant.

**How can the pain and discomfort of intubation be reduced?**

It is ethically imperative to administer analgesia before planned painful interventions unless it can be proven harmful to do so; the reduction of the short-term physiological sequelae is probably, at least in part, secondary to the reduction in pain and discomfort.

**Opiates**

Morphine appears not to reduce the occurrence of severe hypoxia with bradycardia during intubation, in comparison with placebo, probably because of the delayed onset of action [21]. It is likely that fentanyl is more effective because of the more rapid onset of action. Other newer agents that are even faster acting may also be more effective. An example of such an agent is remifentanil, which in older subjects, has an onset of action within seconds and a duration of only a few minutes [22][23]. Limited neonatal pharmacokinetic (PK) and pharmacodynamic (PD) data are available for morphine and fentanyl, but much less are available for remifentanil. A blinded randomized trial [16] showed that...
meperidine reduced the endocrine responses to intubation. The very limited PK or PD data that are available in the neonate show marked interindividual variability of clearance [24].

Barbiturates
A small randomized trial in term and late preterm infants [25] showed that thiopental, an anesthetic barbiturate, reduced apparent pain in newborn infants undergoing intubation compared with no premedication. However, the very prolonged elimination of thiopental in the neonate raises concern (average elimination half-life 14.9 h) [26]. Methohexital, a barbiturate that is very short acting in older subjects, was associated with smooth intubating conditions and no apparent distress during intubation in an uncontrolled study [27]. Currently, there appears to be no PK or PD data for the newborn.

Propofol
A recent randomized controlled trial [28] compared the use of propofol with morphine, atropine and succinylcholine for intubation of newborn infants. Intubation was faster, oxygen saturations better maintained, and recovery time shorter in the propofol group. Concern has been raised that propofol is a hypnotic agent without analgesic effect and that the combination of propofol with an analgesic such as an opioid may be required. Limited PK data show extreme variability in clearance, suggesting that methods for individualizing dosage may be required. In older subjects, propofol commonly causes hypotension [29], and prolonged or repeated use can lead to serious adverse effects; thus, further investigation of single-dose use is required before recommending its widespread use.

Midazolam
Nonanalgesic sedatives, by definition, do not reduce pain and, thus, their use alone for intubation is inappropriate. Midazolam appears to be the most commonly used medication in this category [30]. It has not been shown to reduce any physiological changes of intubation and has been associated with serious adverse effects during intubation [31]. It causes hypotension [31–35], decreased cardiac output [32] and decreased cerebral blood flow velocity [31–34], has variable kinetics with a half-life that can exceed 22 h [36][37] and, when used as a prolonged infusion, has been associated with an increase in adverse neurological outcomes [38]. Midazolam should not be used for intubation purposes in the newborn [28][29].

What are the complications of premedicating an infant for intubation?

The risk of complications is one reason frequently given for not using premedications [40]. None of the randomized controlled trials, however, have demonstrated serious complications from premedication given before intubation. A multicentre observational study in France [30] showed no increase in the frequency of complications when infants were premedicated. The use of potent short-acting opiates is occasionally followed by increased muscle tone including increased tone in the chest wall musculature. This result appears to be relatively infrequent if the medication is given slowly [41], and can be treated by administering a muscle relaxant or opioid antagonist.

Infants are now frequently intubated for the purpose of administering surfactant, with a plan to extubate as soon as they have responded adequately. In such a circumstance, one priority for a premedication regimen should be to avoid prolonged adverse respiratory effects. Although fentanyl has a prolonged serum half-life in the newborn, averaging 10 h or more, it causes only short-lasting respiratory depression, and infants can be safely extubated less than 1 h after its administration. One potential advantage of ultrashort-acting agents such as remifentanil is a very short serum half-life of only a few minutes and, thus, there is less concern about potential residual effects. Future premedication research should examine the effects of the regimen on extubation success.

Under what clinical circumstances is it acceptable to intubate an infant without the use of premedication?

If the risks of the medications exceed the risks to the infant of being intubated without premedication, it would be acceptable to proceed without premedication. This may occur during resuscitation, either in the delivery room, or during acute deterioration or critical illness after the delivery room but during the neonatal period or the neonatal intensive care unit stay. While establishing an airway, procuring adequate ventilation and ensuring a good heart rate, administration of premedication would be inappropriate. However, an infant successfully resuscitated by face mask, who requires
intubation because of an ongoing need for respiratory support, should receive premedication as soon as appropriate vascular access has been established, which could be by peripheral intravenous (IV) access, central access or the umbilical vein.

Infants with extremely difficult vascular access, in whom multiple IV attempts with consequent discomfort are likely, could be considered for an alternative route of medication administration. Alternatives include via the nasal mucosa (eg, fentanyl is effective by this route) or by inhalation (such as with nitrous oxide [42] or sevoflurane [43]); rarely, awake intubation can be considered. Infants with severely abnormal airways who are likely to be difficult to intubate and need to breath on their own should not receive premedication. Bronchoscopic intubation [44] or use of a laryngeal mask airway [45] may be necessary; if the centre does not have experience with these techniques, transfer to an experienced centre, using bag and mask ventilation as backup, should be considered.

Which premedications have been studied?

See Table 1 for a summary of the premedications that have been studied.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vagal blockade</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atropine</td>
<td>Dose requirements known</td>
<td>Potential for CNS complications in overdose</td>
<td>RCT; atropine vs no therapy [12]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>30 Term and preterm newborns</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Prevention of bradycardia compared to no therapy</td>
</tr>
<tr>
<td>Glycopyrrolate</td>
<td>Does not cross the blood-brain barrier</td>
<td>Uncertain dose requirements in the very preterm infant</td>
<td>RCT; given to both groups [16]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>20 Term and preterm newborns</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No bradycardia</td>
</tr>
<tr>
<td><strong>Analgesia/anaesthesia</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fentanyl</td>
<td>Potent opiate; PK data available [43]</td>
<td>Dose requirements for intubation unknown in the newborn, rare occurrence of chest wall rigidity [44], unpredictable sedative effect [45]</td>
<td>Cohort study [40] Used in both arms of numerous small RCTs</td>
</tr>
<tr>
<td></td>
<td>Good analgesic effect</td>
<td></td>
<td>253 Term and preterm newborns</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Showed safety of a protocol including fentanyl and succinylcholine</td>
</tr>
<tr>
<td>Alfentanil</td>
<td>Potent opiate</td>
<td>Dose requirements and kinetics unknown</td>
<td>RCT; in combination with succinylcholine, vs meperidine without muscle relaxant [20]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>20 Term and preterm newborns</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Shorter intubation and reduced duration of hypoxia with alfentanil/succinylcholine</td>
</tr>
<tr>
<td>Morphine</td>
<td>Opiate; PK data available</td>
<td>Dose requirements unknown for this purpose, delayed onset of action limits efficacy for this purpose</td>
<td>RCT; morphine vs no premedication [21]</td>
</tr>
<tr>
<td></td>
<td>Sedative effect</td>
<td></td>
<td>60 Term and preterm newborns</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No effect on severity of physiologic disturbance during intubation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>RCT; in combination with succinylcholine and atropine [17] vs nothing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>20 Term and preterm newborns</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Reduced time to intubate, (60 s vs 590 s), fewer attempts and less bradycardia</td>
</tr>
<tr>
<td>Meperidine</td>
<td>Opiate with sedative effect</td>
<td>Causes nausea in older patients</td>
<td>RCT; meperidine vs alfentanil and succinylcholine [16]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>20 Term and preterm newborns</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>More hypoxia than comparison group</td>
</tr>
<tr>
<td>Remifentanil</td>
<td>Potent opiate</td>
<td>May cause chest wall rigidity, hemodynamic effects uncertain in the newborn, limited PK data in the newborn</td>
<td>RCT; remifentanil vs morphine [46]</td>
</tr>
<tr>
<td></td>
<td>Rapid acting, very rapid clearance and short duration of action, provides good levels of anaesthesia</td>
<td></td>
<td>20 Term and preterm newborns</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>21 Preterm newborns</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Improved intubating conditions with remifentanil</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Good intubation conditions, rapid extubation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>RCT; remifentanil vs fentanyl plus succinylcholine [23]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>30 Term and preterm newborns</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Similar intubation conditions and complications, longer intubations and more chest wall rigidity with remifentanil alone, not statistically significant</td>
</tr>
</tbody>
</table>
### Methohexital

- **Barbiturate analogue**
- **Rapid acting, provides good levels of sedation**
- Unfamiliar to many neonatologists, no PK data
- Cohort study [27]
- 18 Newborns >32 wks’ gestation
- Good sedation and intubating conditions

May cause hypotension, toxicity unknown in the newborn, little data on PK but reduced clearance in the newborn

### Propofol

- **Very rapid acting, provides good levels of anaesthesia**
- Cohort study [50]
- 100 Newborns and infants 2.1 kg to 9.2 kg under halothane anaesthesia
- Short intubation time, excellent intubating conditions

- RCT; propofol vs morphine, succinylcholine and atropine [28]
- 63 Term and preterm newborns
- Shorter intubation and less hypoxia with propofol

### Thiopental

- **Rapid-acting anaesthetic agent**
- Causes hypotension in older children, prolonged and extremely variable clearance
- RCT [29]; thiopental vs nothing
- 30 Newborn infants >2kg
- Blunts hypertensive response

### Muscle relaxation

| Pancuronium | Nondepolarizing agent, few side effects | Prolonged duration | RCT; atropine alone to atropine plus pancuronium vs nothing [12] | 30 | Term and preterm newborns | Similar increase in intracranial pressure and less hypoxia during intubation |
| Succinylcholine | Rapid acting, short duration of action | Depolarizing agent, rare serious complications, malignant hyperthermia, hyperkalaemia, rhabdomyolysis | 4 RCTs (1 only partly randomized) [13][16]-[18] | 81 | Term and preterm newborns | Reduces intracranial pressure increase, shortens duration of the procedure, reduces number of attempts, reduces trauma |
| Mivacurium | Nondepolarizing agent, few side effects, brief duration of action | Cohort study of use in combination with fentanyl and atropine [51] | 34 | Term and preterm newborns | Rapid onset (1-3 min), brief duration of action (5-15 min), very stable intubation conditions |
| Rocuronium | Nondepolarizing agent with rapid onset | Prolonged and variable duration (up to 1 h) | RCT; rocuronium vs no relaxant (all infants received fentanyl and atropine) [48] | 44 | Preterm newborns | Much more likely to be intubated on first attempt compared with controls |

### CNS Central nervous system; PK Pharmacokinetic; RCT Randomized controlled trial; vs Versus; wks Weeks

---

**What are the characteristics of an acceptable protocol for premedication?**

From the above review, it appears that given the current level of knowledge, the optimal protocol is to administer a vagolytic, an analgesic and a muscle relaxant. Further research of hypnotic/anesthetic agents such as propofol will be required before recommending their use.

**Vagolytic**

Glycopyrrolate and atropine are both effective and have not been directly compared. Dose requirements of glycopyrrolate in small preterm infants are not...
known [46]. Atropine has not been associated with significant adverse effects when given once in the correct dosage. It should be noted that there is no minimum total dose – 10 μg/kg to 20 μg/kg is effective and safe.

**Analgesia**
The optimal analgesic for intubation would have a very rapid onset, no effect on respiratory mechanics, a short duration of action with good sedation, and reliable kinetics. None of the currently available agents fit this profile. Fentanyl, the most widely used analgesic agent, blunts physiological disturbance during intubation in adults and older children, and has a good safety profile. No randomized trials of fentanyl as a premedication for intubation compared with other agents are available. Chest wall rigidity is a rare phenomenon at the doses usually given. It can be reversed with naloxone or the immediate administration of a rapid-acting muscle relaxant, or perhaps prevented by coadministration of the relaxant. Fentanyl may reduce respiratory drive; therefore, the team must be ready to maintain an open airway and support the respiration of the infant whenever the drug is given.

According to a number of studies [11][4], morphine is the most commonly used drug for intubation; however, it does not improve physiological stability during intubation when used alone. This may well be because at least 10 min are required for good analgesia after IV administration, suggesting it may not be the optimal drug for analgesia before intubation. The very rapid onset and short duration of action of remifentanil is attractive; it should be further investigated in the newborn. Methohexitol and thiopental have only been studied in larger preterm and term infants, but warrant further investigation.

**Muscle relaxation**
The optimal muscle relaxant for intubation would have a rapid onset, short duration of action and few side effects. Succinylcholine has been most widely used, but has rare serious side effects and causes an increase in blood pressure after use, simultaneously with the depolarization. Hyperkalemia may occur, but major elevations are uncommon and usually seen in association with significant tissue injury [47]. Succinylcholine may trigger malignant hyperthermia, a rare autosomal dominant disorder of skeletal muscle that remains asymptomatic unless triggering substances are given. Succinylcholine should not be used in infants with hyperkalemia or a family history of malignant hyperthermia.

Of the nondepolarizing agents, mivacurium most closely fits the ideal profile. The duration of action of approximately 8 min to 12 min is reasonable for allowing tube fixation after intubation, and will allow rapid weaning and extubation if the infant was intubated for a brief procedure such as surfactant administration. However, mivacurium is not currently available in North America and alternative agents (eg, cisatracurium) should be investigated. Rocuronium has been investigated and has the advantage of a rapid onset of action, but for most purposes, the duration of muscle relaxation (of up to 1 h) is too long and would not be appropriate.

If the decision is made to intubate using a potent opioid but without muscle relaxation, we recommend that a muscle relaxant be drawn up in the correct dosage and be available for use in case of chest wall rigidity. For this purpose, succinylcholine, which has the most rapid onset of action, would be appropriate.

**Other aspects of endotracheal intubation**

Endotracheal intubation is a stressful and potentially dangerous procedure that requires careful monitoring, excellent technique and every effort made to reduce its hazards, in addition to consideration of premedication. Preoxygenation to reduce hypoxia, limiting the duration of attempts to a reasonable maximum duration (such as 30 s), careful observation and monitoring during the procedure (in particular with pulse oximetry), and confirmation of appropriate tube placement with exhaled carbon dioxide detection are required. The procedure should be performed or supervised by individuals with adequate training and experience.

**Recommendations**

- Intubations should be performed (or supervised) by trained staff with knowledge about the effects of the intubation process and the medications used.
- During intubation, the infant should be monitored closely – pulse oximetry is usually the minimum monitoring required.
- All newborn infants should receive analgesic premedication for endotracheal intubation, except for emergency intubations during resuscitation or in-
fants in whom instrumentation of the airway is likely to be extremely difficult (recommendation grade A).

- Vagolytic agents should be strongly considered; atropine at a dose of 20 µg/kg (there is no absolute minimum dose) is effective and safe if given once. 10 µg/kg may be sufficient. (recommendation grade A).

- Rapid-acting analgesic agents should be given; the current best choice is fentanyl (recommendation grade B).

- Infants should receive fentanyl by slow IV infusion (1 min appears to be adequate) and muscle relaxants should be available when fentanyl is given to a nonintubated infant. Alternatively, routine use of a muscle relaxant following fentanyl administration could be considered.

- Rapid-onset muscle relaxants should be considered. Agents of short duration will usually be preferable; succinylcholine in a dose of 2 mg/kg is currently considered to be the best choice (recommendation grade A).

- A suggested protocol is described in Table 2.

- Further research is needed to determine the most appropriate medications and sequence. Newer very rapid-acting agents with short durations of action should be further investigated. Long-term outcomes should be assessed.

### Table 2

<table>
<thead>
<tr>
<th>Medication</th>
<th>Suggested dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atropine</td>
<td>20 µg/kg intravenously</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>3 µg/kg to 5 µg/kg intravenously (slow infusion)</td>
</tr>
<tr>
<td>Succinylcholine</td>
<td>2 mg/kg intravenously</td>
</tr>
</tbody>
</table>

None of these drugs are currently labelled for neonatal use.

**Acknowledgements**

The Canadian Paediatric Society’s Acute Care Committee, Community Paediatrics Committee, and Drug Therapy and Hazardous Substances Committee reviewed this position statement.

**References**


48. Pereira e Silva Y, Gomez RS, de Oliveira Marcatto J, Maximo TA, Barbosa RF, Simões e Silva AC. Morphine

**FETUS AND NEWBORN COMMITTEE**

*Members:* Robert I Hilliard MD (board representative); Ann L Jefferies MD (chair); Abraham Peliowski-Davidovich MD; S Todd Sorokan MD; Hilary EA Whyte MD; Robin K Whyte MD

*Liaisons:* Michael S Dunn MD, Neonatal-Perinatal Medicine Section, Canadian Paediatric Society; Sandra Dunn, Canadian Perinatal Programs Coalition; Andrée Gagnon MD, College of Family Physicians of Canada; Robert Gagnon MD, Society of Obstetricians and Gynaecologists of Canada; Catherine M McCourt MD, Public Health Agency of Canada, Health Canada; Patricia A O’Flaherty, Canadian Association of Neonatal Nurses; Lu-Ann Papile MD, Committee on Fetus and Newborn, American Academy of Pediatrics

*Consultants:* Keith James Barrington MD; Haresh M Kirpalani MD

*Principal author:* Keith James Barrington MD